Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology →$30.61
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses.$25.00($23.00–$27.00)
Target PriceOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology →$35.01
Expected Return
Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Type B - Oscar Health, Inc. (OSCR) 20260716 Stock Analysis
📅 Oscar Health Key Upcoming Events
August 06, 2026Q2 2026 Earnings Release and Conference Call
Description: Oscar Health will release its second-quarter financials, representing a critical juncture to verify whether the historic profitability and unprecedented 70.5% Medical Loss Ratio (MLR) achieved in the first quarter can be sustained. Investors and analysts will rigorously scrutinize management’s commentary regarding intra-year claims seasonality, the stabilization of market morbidity, and ongoing medical cost trends.
November 01, 2026Open Enrollment Period (OEP) Begins for the 2027 Plan Year
Description: The kickoff for the 2027 Affordable Care Act (ACA) open enrollment will serve as a massive fundamental catalyst. With enhanced ACA tax subsidies currently slated to expire, management has preemptively priced in a potential 20% to 30% market shrinkage. This period will definitively test Oscar Health’s competitive positioning, consumer brand loyalty, and ability to capture emerging Individual Coverage Health Reimbursement Arrangement (ICHRA) volumes.
🏢 Step 1: Oscar Health Company Overview & Business Model
Q1-A1. What is Oscar Health?
Company Name (Ticker): Oscar Health, Inc. (OSCR)
Sector: Healthcare
Exchange: NYSE
Founded: November 01, 2012
Listing Date: March 03, 2021
Fiscal Year End: December
Headquarters: United States, New York
CEO: Mark Bertolini
Market Cap: $9.52B
Shares Outstanding: 301.18M
Current Price: $30.61
Annual Dividend Yield: ➖ Not applicable
Ex-dividend Date: ➖ Not applicable
As-of: July 16, 2026 (ET)
Q1-A2. How Does Oscar Health Make Money?
Business Model: Oscar Health operates as a full-stack, technology-driven health insurance company. The enterprise generates the vast majority of its revenue by collecting direct policy premiums from members enrolled in its health insurance plans, primarily targeting the Individual and Family Plan (IFP) market via the Affordable Care Act (ACA) exchanges. Unlike legacy insurers that rely heavily on fragmented third-party administration systems, Oscar Health has built a proprietary, cloud-native technology platform known as “+Oscar” and the “Campaign Builder” engagement tool. This vertically integrated tech stack allows the company to drastically lower administrative expenses, proactively route patient care to high-quality and lower-cost Tier 1 providers, and deliver an intuitive, mobile-first member experience that drives retention and optimizes clinical outcomes.
Q1-A3. Oscar Health’s Revenue Segments & Core Income Sources
Direct Policy Premiums (Individual and Family Plans):
Revenue Share: Accounting for approximately 97% to 98% of total operating revenue.
Significance: This is the absolute core engine of Oscar Health’s top-line growth and operating leverage. The company effectively targets demographic cohorts aged 26-54, encompassing independent gig-economy workers, solopreneurs, and an increasingly critical 55-64 cohort that is bridging the gap to Medicare eligibility. With total membership surging past 3.17 million in the first quarter of 2026, the company relies heavily on the Centers for Medicare & Medicaid Services (CMS) for premium subsidies, as a large share of its members fall between 150% and 400% of the Federal Poverty Level (FPL) and utilize Advanced Premium Tax Credits (APTC).
Investment Income & Ancillary Revenues:
Revenue Share: Comprising the remaining 2% to 3% of total revenue.
Significance: Supported by a formidable balance sheet featuring $6.8 billion in cash and short-term investments, Oscar Health generates substantial investment income in the elevated interest rate environment. While numerically small compared to the billions collected in premiums, this high-margin investment income drops almost directly to the bottom line, serving as a critical buffer for net income profitability during quarters with historically higher claims utilization.
Q1-A4. Who Are Oscar Health’s Competitors?
Direct Competitors: The competitive landscape is dominated by deeply entrenched, mega-cap managed care organizations such as Centene Corporation (CNC), Molina Healthcare (MOH), and Elevance Health (ELV). These legacy incumbents possess massive scale advantages, sprawling national provider networks, and deep institutional relationships with state and federal regulators. Centene and Molina, in particular, heavily overlap with Oscar Health in the government-sponsored health plan arena, specifically within Medicare, Medicaid, and the ACA marketplace.
Substitutes / Complementary: Traditional Employer-Sponsored Insurance (ESI) functions as a structural substitute to the individual market. However, the rapidly growing adoption of the Individual Coverage Health Reimbursement Arrangement (ICHRA) allows Oscar Health to actively convert this substitute into a complementary growth driver, capturing corporate healthcare dollars by migrating employees onto its individual exchange plans.
Disrupted Victim: Regional Blue Cross Blue Shield affiliates and traditional, archaic health insurers are the primary victims of Oscar Health’s disruption. These legacy operators, burdened by decades-old, fragmented IT infrastructure, struggle to offer the pricing transparency and seamless digital engagement that modern consumers demand, making them highly vulnerable to Oscar’s tech-forward customer acquisition strategies.
Strategic Position: Oscar Health fundamentally operates as a Fast Follower with a disruptive technological edge. Rather than attempting to out-scale giants like UnitedHealth Group in sheer capital deployment or national footprint, Oscar competes as an insurtech specialist. It establishes deep, localized integrated delivery systems in select metropolitan areas to control unit economics and differentiates itself purely on consumer experience, dynamic care routing, and administrative scalability.
Q1-A5. What Problem Does Oscar Health Solve?
Pain Points: The legacy United States health insurance ecosystem is notoriously complex, opaque, and hostile to the end consumer. Patients routinely struggle to identify in-network physicians, forecast out-of-pocket medical expenses, and navigate convoluted claims adjudication processes. This systemic friction results in delayed preventative care, over-utilization of expensive emergency facilities, and massive administrative bloat.
Solution: Oscar Health entirely replaces the fragmented legacy infrastructure with a unified, mobile-first digital ecosystem. By providing 24/7 free virtual primary care, transparent cost-estimation tools, and personalized Care Teams, Oscar removes the friction from healthcare navigation. This technological routing efficiency is a dual mandate: it delights the consumer, thereby driving industry-leading Net Promoter Scores (NPS) and retention, while simultaneously lowering Oscar’s core medical costs by deliberately steering members toward high-quality, lower-cost Tier 1 providers and away from unnecessary emergency room visits.
Q1-A6. Oscar Health Key Milestones: Past 12 Months
November 05, 2025Strategic De-leveraging via Convertible Note Exchange
Description: Oscar Health executed an exchange agreement with Dragoneer Investment Group, converting approximately $187.5 million of its 7.25% convertible senior notes due 2031 into 23.3 million shares of Class A common stock. This transaction significantly de-risked the balance sheet and permanently reduced the company’s future interest expense burden.
February 06, 2026Secured a $475 Million Revolving Credit Facility
Description: The company entered into a new three-year secured revolving credit facility syndicated by tier-one institutions including JPMorgan Chase. This maneuver substantially fortified Oscar’s liquidity position, providing flexible working capital without necessitating the liquidation of yield-bearing assets trapped at the regulated subsidiary level.
February 10, 2026Achieved First-Ever Full-Year Net Income Profitability
Description: Management reported a historic milestone, achieving full-year net income profitability of $25.4 million for fiscal 2024, a massive reversal from deep structural losses in previous years. Concurrently, the company outlined a highly confident outlook, projecting a profound return to profitability for 2026 following a difficult 2025 reset year.
May 06, 2026Record Q1 2026 Earnings Spark Massive Stock Rerating
Description: Oscar Health shattered Wall Street expectations, reporting a record $679 million in net income and an unprecedented 70.5% Medical Loss Ratio (MLR) on $4.65 billion in quarterly revenue. The staggering 88% EPS beat definitively proved the viability of the company’s margin expansion strategy, propelling the stock by over 48% in a matter of weeks.
June 04, 2026Siddhartha Sankaran Appointed Independent Chair of the Board
Description: In a move signaling the company’s maturation from a Silicon Valley startup into a heavily regulated, systemically important financial enterprise, Oscar elevated Siddhartha Sankaran to Independent Chair, replacing long-serving chair Jeffery Boyd to enhance corporate governance.
Q1-A7. Step 1 Key Takeaways
Step 1 Summary: Oscar Health has decisively navigated the perilous “growth-at-all-costs” phase that defines many insurtech startups, transitioning into a fundamentally profitable, highly scaled managed care organization. By hyper-focusing its resources on the ACA exchanges and ruthlessly leveraging its proprietary software stack, it is successfully bleeding market share from legacy incumbents. However, the company’s absolute reliance on government subsidies and extreme sensitivity to market morbidity remain deeply embedded structural risks.
Top 3 Red Flags:
1 Extreme concentration risk: Substantially all of Oscar Health’s revenue is derived from the heavily regulated ACA exchange market, rendering the company acutely vulnerable to sudden legislative or policy shifts.
2 Regulatory vulnerability: Underlying profitability is highly sensitive to the opaque CMS Risk Adjustment transfer formulas, which previously triggered massive, unexpected financial losses for the company during the 2025 fiscal year.
3 Insider selling pressure: Sustained high-volume share sales by core insiders, including CEO Mark Bertolini and Founder Mario Schlosser, create optical headwinds and dampen retail investor sentiment, even when executed under structured 10b5-1 tax plans.
Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
1 The trajectory of the Medical Loss Ratio (MLR) versus seasonal expectations.
2 Membership growth and retention metrics specifically within the Individual Exchange.
3 The Selling, General, and Administrative (SG&A) expense ratio as the ultimate proof of technological operating leverage.
4 The magnitude and direction of Net Risk Adjustment transfer accruals.
5 Operating Cash Flow generation relative to statutory capital requirements.
Top 3 Unconfirmed and Estimated:
1 The precise financial impact of the anticipated expiration of enhanced ACA premium subsidies, which management projects could shrink the total market by 20% to 30%.
2 The adoption velocity and margin profile of the emerging Individual Coverage Health Reimbursement Arrangement (ICHRA) market segment.
3 The timeline and feasibility of monetizing the “+Oscar” technology platform as an independent software-as-a-service (SaaS) revenue stream to third-party payers.
Q2-A1. Does Oscar Health Have a Durable Economic Moat?
Technology and Data Monopoly: Oscar Health possesses a moderate but highly differentiated technological moat. Its cloud-native, custom-built infrastructure, encompassing the +Oscar and Campaign Builder systems, enables real-time data integration and personalized member engagement. Legacy insurers, burdened by decades-old, siloed patchwork systems resulting from endless M&A activity, fundamentally struggle to replicate this agility. This data superiority allows Oscar to execute dynamic pricing, predictive clinical interventions, and highly efficient care routing.
Network Effects and Scalability: The network effect in health insurance is strictly localized. Oscar builds deep provider density in specific target markets (e.g., Florida, Texas, California) rather than attempting a shallow national rollout. As Oscar scales its covered lives within a specific county, it gains negotiating leverage to secure lower reimbursement rates with local health systems. This allows Oscar to lower consumer premiums, which in turn attracts more members, creating a localized flywheel. Furthermore, Oscar’s strategy heavily utilizes quota share reinsurance—currently covering roughly 55% of required capital—which acts as a structural mechanism to aggressively scale membership without breaching statutory capital requirements.
Switching Costs: Traditionally, switching costs in the ACA marketplace are exceptionally low, as consumers aggressively shop for the lowest monthly premium during Open Enrollment. Oscar Health strategically mitigates this vulnerability through deep technological integration. Members who habituate to Oscar’s free 24/7 virtual primary care, integrated biometric health tracking, and dedicated Care Teams experience substantial psychological and convenience-based friction if they revert to a clunky, traditional legacy provider.
Brand and Fandom: Oscar Health boasts a Net Promoter Score (NPS) that is significantly higher than the dismal industry average. Its intuitive mobile application and consumer-friendly, transparent branding create unusually sticky relationships in an industry that is universally despised by the average American consumer.
Pricing Power: Pricing power is strictly constrained by state insurance regulators and intense competitive pressures. Oscar cannot unilaterally raise premiums without sacrificing massive market share. However, its lower administrative cost base provides a hidden form of pricing power, allowing the company to maintain margins even when undercutting legacy peers on price.
Q2-A2. How Big Is Oscar Health’s Market? (TAM)
Total Addressable Market (TAM): The United States health and medical insurance market is a colossal arena, valued globally at approximately $2.4 trillion in 2025 and projected to expand significantly. Specifically, Oscar Health targets the Individual (ACA) market, which currently covers tens of millions of Americans. With the rising corporate adoption of the Individual Coverage Health Reimbursement Arrangement (ICHRA), the TAM is poised for aggressive expansion as employers increasingly shift their workers away from traditional group health plans and onto the individual exchanges.
Market Growth Rate (CAGR): The broader global health insurance market is compounding at roughly 6.7% annually. However, the specific ACA exchange sub-market has experienced explosive double-digit growth in recent years, propelled by the unwinding of pandemic-era Medicaid continuous enrollment and the implementation of enhanced federal tax credits.
Upside Potential: Given Oscar Health’s current market capitalization of approximately $9.5 billion and its reaffirmed guidance of roughly $18.7 billion to $19.0 billion in total revenue for 2026, the company possesses immense runway. Capturing even a fractional percentage of the legacy employer-sponsored market via ICHRA could multiply the company’s scale exponentially.
Q2-A3. How Real Is Oscar Health’s TAM? (Quality Check)
Willingness to Pay (WTP): Willingness to pay is robust but artificially subsidized. A massive portion of Oscar’s members—specifically those earning between 150% and 400% of the Federal Poverty Level—utilize Advanced Premium Tax Credits (APTCs). WTP is strong precisely because the federal government subsidizes the actual premium cost, making the market highly lucrative but entirely dependent on legislative and political stability.
Market Structure: The health insurance market is fragmented at the national macro level but intensely concentrated at the micro, local level. It operates as a cutthroat pricing oligopoly where the top two or three insurers in a specific county capture the overwhelming majority of lives.
Regulation/Entry Barriers: Entry barriers are exceptionally high. Establishing a functional health insurance company requires massive, locked-up statutory capital, excruciating state-by-state regulatory rate approvals, and the grueling process of contracting deep provider networks. This creates a massive moat against new entrants, structurally protecting Oscar’s established footprint.
Q2-A4. Can Oscar Health Keep Expanding Its Market?
Penetration Rate: Oscar Health currently covers approximately 3.17 million lives out of a total U.S. population of 330 million, representing early-stage penetration with massive long-term runway.
Structural Scalability: The business model is highly scalable on the administrative backend due to its cloud-native tech stack, which exhibits near-zero marginal cost for adding a new member to the digital ecosystem. However, core medical costs (claims) scale linearly. This dictates that while Oscar can onboard members infinitely, it must constantly manage clinical risk and provider pricing to prevent scaling its losses.
Expansion Strategy: Oscar employs a deliberate, localized strategy. By 2025, the insurer operated in 18 states and over 500 counties, concentrating its market share in high-density, high-growth metropolitan areas rather than pursuing unprofitable nationwide breadth. This includes tailored product rollouts, such as a 2025 Spanish-first initiative targeting a rapidly growing Hispanic demographic cohort.
Economic Moat (8/10): The proprietary technology stack, exceptional consumer NPS, and sophisticated use of quota share reinsurance provide a robust edge, though fundamental switching costs remain vulnerable to premium pricing.
Market Size (5/5): The United States healthcare TAM is essentially limitless, and the specific ACA and ICHRA segments are expanding rapidly.
Market Quality·Profitability (4/7): High regulatory barriers heavily protect the business from startups, but the absolute reliance on government subsidies caps the fundamental quality and safety of the market.
Market Penetration·Scalability (6/8): Administrative functions scale beautifully via software, but the linear nature of medical claims demands rigorous, localized risk management that restricts infinite scalability.
Step 2 Summary: Oscar Health attacks a massive, legally mandated market equipped with a vastly superior consumer technology product. While the business inherently lacks the unilateral pricing power of a pure software enterprise, its high regulatory entry barriers and tech-driven administrative scalability provide a durable foundation for massive multi-year expansion.
🚀 Step 3: How Fast Is Oscar Health Growing? Hyper-Growth Metrics
Q3-A1. How Fast Is Oscar Health Growing? (Revenue Trajectory)
J-Curve Revenue Growth: Oscar Health has exhibited explosive, hyper-growth top-line metrics. Total revenue surged from $5.86 billion in FY2023 to $9.18 billion in FY2024, and further to $11.7 billion in FY2025.
Acceleration Profile: Rather than slowing down as the law of large numbers takes effect, growth is actually accelerating. In the first quarter of 2026, Oscar generated an astounding $4.65 billion in total revenue, representing a massive 52.55% year-over-year growth rate compared to the $3.05 billion generated in Q1 2025. The company is actively accelerating its top-line trajectory, completely eclipsing its own long-term target of a 20% revenue CAGR.
Rationale: In the managed care and health insurance sector, the ability to acquire covered lives and retain them over multiple annual billing cycles is the ultimate determinant of premium revenue scale and risk-pool stabilization.
Performance: Oscar’s total membership skyrocketed from 2.04 million in Q1 2025 to 3.17 million in Q1 2026. This incredible ≈55% surge proves definitively that Oscar’s pricing strategy, tech-forward appeal, and targeted demographic marketing are highly effective in capturing the uninsured and those transitioning off Medicaid redeterminations. Notably, this growth occurred entirely within the Individual and Small Group offerings following the strategic wind-down of the Cigna+Oscar arrangement.
Q3-A3. Are Oscar Health’s Unit Economics Improving?
Medical Loss Ratio (MLR): Oscar Health is demonstrating exceptional, hard-proof improvement in its core unit economics. The MLR—which tracks the percentage of premium dollars paid out for medical claims—dropped substantially from 75.4% in Q1 2025 to an industry-leading 70.5% in Q1 2026. This 490 basis-point improvement indicates that Oscar’s premium pricing is comfortably outpacing clinical claims utilization, aided by disciplined pricing strategies, favorable claims seasonality, and $68 million in favorable prior-period reserve development.
Operating Efficiency: The SG&A expense ratio improved from 15.8% to 15.2% year-over-year in Q1 2026. This validates the core “tech-stack” investment thesis: as revenue scales into the tens of billions, Oscar’s proprietary backend software allows fixed costs to be leveraged efficiently without requiring a proportional, linear increase in administrative headcount.
Revenue Growth Acceleration (11/12): Generating over 52% year-over-year revenue growth at a $13 billion to $18 billion scale is an exceptional execution of market share capture.
Sector-Specific Growth Metrics (9/10): Adding over 1.1 million net new members in a single year definitively proves that the product resonates, though managing the risk profile of this massive new cohort remains an ongoing challenge.
Unit Economics & Margin (8/8): The drastic 490 basis-point improvement in MLR and the continued SG&A leverage perfectly prove that the technology-driven unit economics model works flawlessly at scale.
Step 3 Summary: Oscar Health is delivering blistering top-line hyper-growth while simultaneously executing massive improvements in its unit economics. The combination of 52.5% revenue expansion and a drastic reduction in the Medical Loss Ratio is the absolute gold standard for an insurtech scaling into a mature enterprise.
Margin Trajectory & BEP: Oscar Health achieved a monumental milestone by recording its first full-year net income profitability in 2024 ($25.4 million). While the 2025 fiscal year saw a painful relapse into unprofitability (a net loss of $443 million) due to severe market-wide morbidity issues and massive CMS risk adjustment transfer penalties, the first quarter of 2026 demonstrated a massive, structural turnaround.
Profit Expansion: In Q1 2026, Earnings from Operations skyrocketed to $704.1 million, a staggering increase from the $297.1 million reported in Q1 2025. Net income attributable to Oscar reached an unprecedented $679.0 million, representing $2.07 in diluted earnings per share. The company has emphatically proven its operating leverage, confirming management’s guidance for meaningful, sustained full-year profitability in 2026.
Q4-A2. Does Oscar Health Generate Free Cash Flow?
FCF Generation Power: Oscar Health’s cash generation capabilities are staggering in the current cycle. In the first quarter of 2026 alone, the company generated $2.619 billion in operating cash flow, drastically outperforming historical metrics.
Self-Funding: This massive cash influx has swelled the balance sheet to $4.83 billion in cash, cash equivalents, and restricted cash, and roughly $6.8 billion when including short-term investments. Oscar is now entirely self-funding its explosive growth. Holding only ≈$431 million in long-term debt, the company has completely eliminated the near-term risk of relying on dilutive external equity financing to survive.
Operating Leverage·Path to Profit (7/8): The Q1 2026 net income of $679 million proves massive profitability potential; however, the cyclical nature of insurance claims, which typically peak later in the year, requires consistent execution to earn a perfect score.
FCF & Capital Efficiency (7/7): Generating $2.6 billion in quarterly operating cash flow and holding $6.8 billion in total liquidity secures the balance sheet with supreme capital efficiency.
Step 4 Summary: Oscar Health has decisively annihilated the market’s doubts regarding its fundamental profitability. With a fortress balance sheet and billions in operating cash flow, the company has successfully transitioned from a cash-burning tech startup into a financially self-sustaining managed care powerhouse.
👔 Step 5: Oscar Health Management & Shareholder Alignment
Q5-A1. Who Leads Oscar Health? (Founder & Management)
Leadership Profile: CEO Mark Bertolini, a highly respected veteran executive and the former CEO of Aetna, brings unparalleled legacy healthcare and regulatory expertise to the helm. This perfectly balances the vision of Co-founder Mario Schlosser, who transitioned to CTO/Advisor to focus entirely on extending Oscar’s technological disruption.
Transparency & Guidance: Management has cultivated a reputation for clear, conservative, and brutally honest communication. During the severe market morbidity crisis of 2025, they accurately modeled the downturn, rapidly reset Wall Street expectations, and then drastically over-delivered in Q1 2026 while confidently reaffirming their long-term guidance.
Q5-A2. Is Oscar Health’s Management Aligned With Shareholders?
Insider Trading: Recent regulatory filings reveal significant insider selling activity. Between June and July 2026, CEO Mark Bertolini sold over 2.4 million shares (valued at over $70 million), and Co-Founder Mario Schlosser engaged in heavy selling of hundreds of thousands of shares at multi-year high prices. While these transactions were primarily executed under pre-arranged 10b5-1 trading plans designed to satisfy tax obligations related to the vesting of stock-based compensation, the sheer volume and optical weight of insiders dumping stock at peak valuations inevitably pressures retail sentiment.
Compensation & Alignment: Management’s equity structure ensures that their ultimate wealth is tied to long-term market capitalization. However, the heavy utilization of Stock-Based Compensation (SBC) has historically diluted external shareholders, as evidenced by the outstanding share count creeping from 240 million to over 301 million.
Founder Management & Vision (7/8): Bertolini’s deep industry experience seamlessly merged with Schlosser’s original technological disruption creates an elite, dual-threat management tandem.
Alignment·Accountability (5/7): While structured 10b5-1 plans logically explain the mechanics of the sales, the optical reality of massive, multi-million dollar insider selling right after an earnings pop detracts from the alignment score.
Step 5 Summary: Oscar Health boasts a highly capable, visionary management team that has successfully steered the company through a challenging ACA landscape into record profitability. However, heavy insider selling and historic shareholder dilution place a ceiling on perfect alignment.
⛵ Step 6: Oscar Health Market Flow & Sentiment
Q6-A1. Analyst Consensus vs Oscar Health Guidance
Expectations vs Reality: Wall Street fundamentally misunderstood the velocity of Oscar’s margin turnaround. In Q1 2026, Oscar Health delivered $2.07 in diluted EPS, utterly destroying the consensus estimate of just $1.10 to $1.12, representing a massive 85% to 88% earnings beat.
Estimate Revisions: Following the Q1 blowout, analysts from major firms including Barclays, Wells Fargo, and TD Cowen have scrambled to upgrade the stock, aggressively raising forward EPS estimates and price targets. This indicates that the institutional consensus is rapidly abandoning its cautious stance and playing aggressive catch-up to the company’s actual operating performance.
Q6-A2. What Is Oscar Health’s Short Interest?
Short Interest & Squeeze Potential: Current short interest stands at approximately 17.47 million shares, representing 6.84% of the float, with a days-to-cover ratio of 3.23 days.
Institutional Trends: This moderate short interest suggests that a healthy degree of skepticism remains among hedge funds regarding the sustainability of the MLR improvements into the heavier-utilization back half of the year. However, it is not high enough to indicate extreme fundamental distress, nor is it primed to guarantee a violent, mechanics-driven short squeeze.
Consensus vs Guidance (3/3): The massive 88% EPS beat definitively proves that management’s internal execution and algorithmic pricing are far outstripping Wall Street’s conservative modeling.
Supply/Short Interest (1/2): Short interest is moderate; there is no immediate squeeze dynamic, but sufficient skepticism remains to provide a healthy “wall of worry” for the stock to climb.
Step 6 Summary: Market sentiment has shifted violently from deeply skeptical to bullishly surprised. As analysts continue to upgrade estimates to match management’s reaffirmed profitability guidance, institutional tailwinds are strongly supporting the stock’s upward trajectory.
🧨 Step 7: Oscar Health Catalysts & Price Triggers
Q7-A1. What Could Re-Rate Oscar Health Stock? (Next 12 Months)
ICHRA Market Expansion: As major employers increasingly adopt Individual Coverage Health Reimbursement Arrangements (ICHRA) to offload volatile corporate health insurance burdens, Oscar is perfectly positioned to capture these millions of transitioning lives. The company’s recent launch of the ICHRA X platform serves as a direct catalyst to bleed market share from traditional ESI providers.
Sustained Profitability (Breakeven Catalyst): The ultimate catalyst has already triggered in Q1. Proving that Q1 2026 was not a seasonal fluke and delivering consecutive quarters of positive GAAP EPS will force the market to permanently re-rate Oscar from a “cash-burning speculative insurtech” to a “highly profitable managed care organization.”
Q7-A2. Oscar Health’s Estimate Revision Trend
Revenue/EPS Revisions: Analysts are aggressively raising forward EPS estimates. The full-year 2026 and 2027 revenue targets are being consistently nudged upward, with forecasts targeting $18.5 billion for 2026 and $19.7 billion for 2027. Oscar’s 3.17 million membership base provides a highly predictable, massive stream of recurring premium revenue that justifies these upward revisions.
Catalyst Strength (2/3): The transition to sustained GAAP profitability is a uniquely powerful rerating engine, though regulatory shifts regarding ACA subsidies remain an exogenous wildcard that caps the perfect score.
Estimated Trend (2/2): Analysts are actively and aggressively revising EPS and revenue estimates upward in direct response to the massive Q1 earnings beat.
Step 7 Summary: The combination of aggressive upward earnings revisions, the structural tailwind of the ICHRA market, and the proof of operational leverage provides a highly credible runway for continued valuation expansion over the next 12 months.
⚖️ Step 8: Is Oscar Health Fairly Valued? Valuation Analysis
Q8-A1. Oscar Health’s Key Valuation Multiples
PS Ratio: 0.69x (undervalued)
P/FCF Ratio: 3.47x (very undervalued)
EV/EBITDA Ratio: 133.99x (very overvalued)
Forward PE: 26.72x (fairly valued)
Scoring Rationale: While the EV/EBITDA ratio looks artificially skewed due to the heavy trailing loss-making quarters of 2025, the Forward PE of 26.72x is highly reasonable for a hyper-growth stock. More importantly, trading at just 0.69x Sales and an incredible 3.47x Free Cash Flow suggests the market is deeply discounting its massive top-line scale and current cash generation power.
📌 (1) Axis Q8-A1 Score:+3
Q8-A2. Oscar Health vs Peers: Valuation Comparison
Multiple selection based on peer comparison: Forward PER is prioritized, as Oscar and its legacy peers are currently profitable on a forward basis.
Calculation of peer-to-peer deviation rate: +212.5%
🧮 Calculation Formula: ((Oscar Forward PE 26.72x - Peer Mean 8.55x) / Peer Mean 8.55x) × 100
Note: The Peer Mean is derived from direct competitors Centene (Forward P/E of roughly 8.05x) and Molina Healthcare (Forward P/E around 9x to 10x based on 2026 estimates).
Scoring Rationale: Compared directly to legacy managed care operators like Centene and Molina, Oscar Health trades at a massive premium exceeding 200% on an earnings basis. The market is forcing investors to pay up heavily for Oscar’s growth profile, making it extremely expensive strictly on a relative peer basis.
📌 (2) Axis Q8-A2 Score:-4
Q8-A3. What Is Oscar Health Worth in the Future? (Forward Valuation)
Implied Future Multiple: Based on the 2027 consensus revenue estimate of approximately $19.76 billion and a current market cap of $9.52 billion, Oscar’s implied future PS ratio is a deeply discounted 0.48x.
Scoring Rationale: An implied future PS of 0.48x is highly reasonable and aligns almost perfectly with the mature industry standard for managed care (typically ranging from 0.3x to 0.6x). The current market capitalization adequately, but not excessively, prices in the company’s future revenue scale over the next two years.
📌 (3) Axis Q8-A3 Score:0
Q8-A3-1. What Growth Hurdle Does the Market Demand From Oscar Health? (Forward Valuation Alternative)
Scoring Rationale: ➖ (Not applicable, as Q8-A3 was calculated).
📌 (3) Axis Q8-A3-1 Score:➖
Q8-A4. Final Valuation Adjustment
Scoring Rationale: A strict mathematical peer comparison severely penalizes Oscar for trading at a massive premium to legacy insurers. However, Centene and Molina are currently battling declining revenues and Medicaid redetermination headwinds, resulting in low single-digit or negative growth. Conversely, Oscar just posted 52.5% YoY revenue growth. A minor premium adjustment is granted to account for the company’s hyper-growth trajectory and digital-first moat, which the legacy peers fundamentally lack.
Commentary: Oscar Health’s valuation is perfectly balanced on a macro level. It is highly expensive compared to slow-growing legacy peers, but incredibly cheap relative to its own cash flow generation and staggering top-line growth velocity. The market has priced the stock with remarkable efficiency, perfectly weighing its risks against its exceptional momentum.
Step 8 Summary: The stock is neither dangerously overvalued nor a deep-value bargain. The valuation adjustment score of exactly zero reflects a perfectly efficient pricing of the company’s hyper-growth profile.
💀 Step 9: What Are the Risks of Oscar Health? Fatal Risks & Pre-Mortem
Q9-A1. Is Oscar Health Burning Cash & Diluting Shareholders?
Cash Exhaustion: With over $4.8 billion in cash, cash equivalents, and restricted cash, and having generated $2.6 billion in quarterly operating cash flow, there is absolutely zero risk of cash exhaustion in the near term.
Dilution: Share counts have steadily crept upward from roughly 240 million to over 301 million over the past few years. This dilution is driven by aggressive stock-based compensation (SBC) necessary for tech talent retention, and the conversion of massive convertible debt notes into equity. While this successfully de-leveraged the balance sheet, it acts as a consistent, mathematical drag on future EPS.
Q9-A2. Do Competition or Regulation Threaten Oscar Health?
Intensifying Competition: The ACA market is a hyper-competitive bloodbath. Giants like UnitedHealth, Centene, and Molina possess infinite capital to under-price Oscar in localized markets if they choose to engage in a predatory price war.
Regulatory Risk: Oscar’s ultimate survival is intimately tied to the federal government. Changes to the opaque CMS Risk Adjustment formula (which severely hurt the company in 2025) or the potential expiration of enhanced ACA tax subsidies could devastate the top line overnight. CFO Scott Blackley explicitly noted that management is pricing in a 20% to 30% market shrinkage scenario for 2026 due to the expiration of enhanced subsidies.
Q9-A3. Oscar Health Pre-Mortem: What Could Go Wrong?
Pre-Mortem Scenario: “One year from now, Oscar’s stock has crashed 65%. The reason: A gridlocked Congress officially allowed the enhanced ACA premium subsidies to expire, causing 30% of Oscar’s members to drop coverage entirely as premiums skyrocketed out of reach. Simultaneously, an unfavorable retroactive CMS risk-adjustment ruling forced Oscar to pay hundreds of millions back into the federal pool, instantly destroying the newly found operating margins and plunging the company back into severe cash burn.”
Q9-A4. Risk Adjustment Score Calculation
📊 Risk Adjustment Score:- 8 pts
Reason for Calculation: Oscar Health has entirely eliminated bankruptcy risk via massive operating cash flow. However, the existential reliance on government ACA subsidies, combined with management actively modeling for a 20% to 30% market shrinkage due to subsidy expiration, warrants a significant deduction for systemic regulatory vulnerability.
Step 9 Summary: Oscar Health is financially secure and operationally sound, but its ultimate destiny is chained to the political and regulatory stability of the Affordable Care Act subsidies.
🎯 Step 10: Oscar Health Final Verdict: Score & Rating
Commentary: A mechanical score of 77 places Oscar Health solidly in the B Rating (Hold) tier. The company excels brilliantly in top-line growth, free cash flow generation, and technological execution, scoring high across fundamental metrics. However, it receives heavy, unavoidable natural gravity from a demanding peer valuation comparison and massive regulatory exposure.
Q10-A2. Should You Buy Oscar Health? (Recommendation)
Recommendation:Hold
Commentary: At current levels, Oscar Health has already experienced a massive ≈165% run-up since earlier this year, efficiently pricing in the historic Q1 2026 earnings beat. Investors should comfortably maintain current positions to capture the ongoing profitability story, but wait for a structural pullback or broader market consolidation before deploying fresh capital.
Q10-A3. Investment Thesis in One Line
Thesis: Oscar Health is a hyper-growth, tech-enabled disruptor rapidly seizing ACA market share and achieving record profitability, but its massive premium valuation relative to legacy peers and absolute reliance on federal health subsidies cap the near-term upside.
Q10-A4. Oscar Health’s Price Trend & Key Drivers
Stock Price Trend Over the Past 12 Months:Upward 📈
May 06, 2026Massive Q1 2026 Earnings Blowout
Description: The company reported a record $679 million net income and a 52.5% revenue surge, utterly destroying consensus EPS estimates by over 85% and proving definitively that the business model can scale highly profitably. 👉 Stock Price Surge
June 15, 2026Favorable Medical Loss Ratio Stabilization
Description: Continued data showing that market morbidity was normalizing and clinical utilization was lower than feared caused a continuous bid under the stock through early summer, driving it to multi-year highs. 👉 Stock Price Steady Climb
July 01, 2026Heavy Insider Selling Disclosures
Description: Regulatory filings revealed CEO Mark Bertolini and CTO Mario Schlosser dumped millions of shares. While executed as part of structured 10b5-1 tax-obligation plans, the optical weight at peak prices cooled the blistering momentum. 👉 Stock Price Sideways/Slight Decline
Q10-A5. Action Plan
Current Price:$30.61
Buy Zone:$25.00 ($23.00–$27.00)
Commentary: This zone balances the need for a Margin of Safety against the reality of Oscar’s extreme price momentum.
(1) Calculation of Fundamental Value: By applying a conservative 15x forward P/E to the 2027 EPS estimates, the intrinsic floor sits closer to $23.00, providing a solid technical support level established before the latest earnings gap-up.
(2) Momentum Premium/Discount Application: Given the 50%+ revenue growth rate, a strict intrinsic floor is rarely hit unless broader markets panic. Allowing a slight premium to catch the $25.00 midpoint ensures entry before institutional algorithms step in to buy the dip.
(3) Conclusion: A buy entry at $25.00 allows investors to participate in the structural ACA shift without overpaying at the absolute top of the current momentum cycle.
Target Price:$35.01
Expected Return:+14.4% (vs. current price)
📍 Select target stock price calculation criteria:
Forward PER based — Oscar Health has turned definitively profitable, making forward earnings-based valuation the most accurate measure of terminal value.
🧮 Target Price Calculation Formula:
$1.49 × 23.50x = $35.01
Basis for applying the multiple: A 23.50x multiple is applied to the forward 2027 EPS estimate of $1.49. This represents a massive premium over legacy peers like Centene (8x) and Molina (14x), but is completely justified by Oscar’s hyper-growth trajectory (50%+ YoY vs low single digits for peers) and its superior digital platform, aligning precisely with the high end of analyst consensus targets.
Conditions and timing for reaching target price: Achievement of the target price requires Q2 and Q3 2026 earnings to strictly maintain the MLR below 80%, and for Congress to strongly signal an extension of the enhanced ACA subsidies prior to the November 2026 Open Enrollment Period.
Stop Loss & Investment Thesis Invalidation Criteria:$19.00 ($18.00–$20.00)
Fundamental invalidation lines: A structural breakdown where the Medical Loss Ratio spikes uncontrollably back above 85%, or a formal announcement that ACA enhanced subsidies will expire without replacement, instantly destroying the TAM expansion thesis and shrinking the market by the projected 20% to 30%.
Action trigger upon catalyst achievement:
1 Consecutive Quarters of >$1.00 EPS Confirmation
Description: Proves that the Q1 2026 performance was a structural baseline, not a seasonal fluke, cementing the company as a cash-generating machine. 👉 Increased Holdings (Buy)
2 Major Enterprise ICHRA Contract Win
Description: Validates the thesis that Oscar can cannibalize the traditional, highly lucrative ESI market using its tech-forward platform. 👉 Increased Holdings (Buy)
Action triggers when risk realization:
1 Expiration of Enhanced ACA Subsidies Confirmed
Description: This would mechanically wipe out millions of covered lives from the exchanges, shrinking Oscar’s total addressable market instantly and triggering massive adverse selection. 👉 Reduction in Holdings (Sell)
2 Sudden Spike in Medical Loss Ratio (>85%)
Description: Indicates that pricing algorithms have failed to predict clinical utilization, threatening a rapid return to massive cash burn. 👉 Reduction in Holdings (Sell)
Customized Strategy Guide by Investment Preference:
Defensive Investors: Wait patiently for the $23.00 lower bound. The regulatory risks surrounding government healthcare policy are too binary for conservative portfolios to chase at a 200% premium to legacy peers.
Neutral Investors: Accumulate slowly via dollar-cost averaging in the $25.00 mid-band. Sell out-of-the-money covered calls to generate yield while waiting for regulatory clarity regarding the subsidy cliff.
Aggressive Investors: Initiate a starter position near current levels ($30.61) to ride the post-earnings momentum, keeping tight trailing stops and adding aggressively on any temporary dips toward the $27.00 level.
Long-Term Tenbagger Vision:
To reach a $95B market cap (a true tenbagger), Oscar must capture roughly 25% of the total Individual and emerging ICHRA markets, requiring sustained annual revenue of $60B+ and a massive expansion of its tech-platform licensing to third-party providers over the next decade.
Tenbagger Reverse Simulation:
Current Market Cap × 10 = $95.2 billion
Revenue scale required to justify it = $65.0 billion
Share of TAM required = ≈20%
Duration at current CAGR = approximately 7 years
🕵️♂️ Deep Dive Analysis
Q1: Is Oscar Health’s Absolute Reliance on the ACA Individual Market Its Biggest Weakness?
Analysis: Oscar Health currently derives approximately 97% to 98% of its revenue and covered lives purely from the Affordable Care Act (ACA) Individual and Family Plan exchanges. While this hyper-focus has allowed the company to tailor its technology specifically to the individual consumer, it leaves the enterprise critically and existentially exposed to legislative stroke-of-the-pen risk. The enhanced premium tax credits, which have driven record enrollment across the industry, are currently subject to political expiration. If these subsidies vanish, management’s own internal models anticipate a market shrinkage of 20% to 30%. A significant portion of Oscar’s 3.17 million members will be priced out of the market entirely, leading to severe top-line contraction and brutal adverse selection, where only the sickest, most expensive members retain their coverage.
Judgment:Negative — The profound lack of diversification into more stable, commercial employer-sponsored plans or mature Medicare Advantage books makes Oscar Health highly vulnerable to exogenous political shocks that are entirely outside of management’s operational control.
Q2: Can Oscar Health’s 24.4x Forward P/E Be Justified Against Legacy Insurers Trading at Single-Digit Multiples?
Analysis: On the surface, paying roughly 24 times forward earnings for Oscar Health appears absurd when established, massive giants like Centene (CNC) and Molina Healthcare (MOH) trade at mid-to-low single digits (roughly 8x and 14x, respectively). However, valuation is inherently a function of forward growth. Centene is currently facing declining revenues and severe Medicaid redetermination headwinds, resulting in a stagnant or negative growth profile. Conversely, Oscar just posted a staggering 52.5% year-over-year revenue surge and a historic 490 basis-point improvement in its Medical Loss Ratio. The premium multiple is paying for Oscar’s transition from a loss-making startup to a scalable, tech-enabled platform that leverages fixed costs far better than legacy peers running on outdated IT systems.
Judgment:Fairly Valued — The massive premium is entirely justified by the velocity of Oscar’s top-line growth and the incredible operating leverage demonstrated in recent quarters, provided the company can sustain its 20%+ forward growth targets over the next 24 months.
Q3: How Will the Expiration of Enhanced ACA Subsidies Impact Oscar Health’s 2027 Revenue Trajectory?
Analysis: The enhanced ACA subsidies implemented during recent administrations have artificially inflated the willingness to pay (WTP) of millions of Americans, allowing them to purchase premium health plans for near-zero out-of-pocket monthly costs. These subsidies are slated to expire, creating a massive fiscal cliff. Oscar Health CFO Scott Blackley explicitly noted at the Raymond James Conference that the company is modeling and pricing for a 20% to 30% market shrinkage due to this expiration. If Congress fails to renew these subsidies, Oscar will lose hundreds of thousands of healthy members who simply stop paying premiums, mechanically dragging down 2027 revenue and crushing the current momentum narrative.
Judgment:Negative — This represents a massive, looming macro headwind that threatens to permanently derail the company’s hyper-growth trajectory if not resolved by federal legislation before the 2027 Open Enrollment Period.
Q4: Does the Heavy Volume of Insider Selling by Oscar Health Executives Signal Internal Fundamental Weakness?
Analysis: Recent SEC Form 4 filings reveal that top executives, including CEO Mark Bertolini and Co-founder/CTO Mario Schlosser, have offloaded tens of millions of dollars in stock following the massive Q1 2026 earnings beat. While retail investors frequently interpret this as a lack of confidence, the underlying mechanics indicate otherwise. These sales are largely executed under pre-planned 10b5-1 trading programs explicitly designed to satisfy heavy tax obligations related to the vesting of stock-based compensation. Furthermore, Bertolini and Schlosser still retain massive equity stakes tied directly to the long-term performance of the company.
Judgment:Neutral — The optics of peak-price selling generate negative retail sentiment and immediate technical headwinds, but the underlying execution of structured tax-selling does not logically indicate a deterioration in the company’s fundamental health.
Q5: Is Oscar Health’s Dramatic Q1 2026 MLR Improvement to 70.5% a Sustainable Baseline or a Seasonal Anomaly?
Analysis: Oscar Health’s Medical Loss Ratio plummeted to a phenomenal 70.5% in Q1 2026, a massive improvement from 75.4% the prior year. Management attributes this to highly disciplined pricing, favorable prior-period reserve development ($68 million), and lighter-than-expected market morbidity. While the structural improvements in care routing are permanent, the 70.5% figure is heavily skewed by favorable seasonality and reserve releases. Health insurance inherently experiences higher MLRs in the second half of the year as members meet their deductibles and schedule elective procedures.
Judgment:Neutral — While the underlying unit economics have genuinely improved, investors must expect the MLR to normalize into the low 80% range for the full year. Modeling a permanent ≈70% MLR will lead to dangerous overvaluations and inevitable disappointment in Q3 and Q4.
Q6: How Does the Expiration of the Cigna+Oscar Partnership Impact Oscar Health’s Long-Term Strategy?
Analysis: Oscar Health previously partnered with Cigna to offer small group plans, attempting to leverage Cigna’s massive provider network alongside Oscar’s slick technology. The strategic wind-down of this partnership initially raised severe concerns about Oscar’s ability to survive outside the individual market. However, exiting the complex, low-margin small group market allowed management to redirect all statutory capital, underwriting focus, and marketing spend exclusively to the exploding ACA and ICHRA exchanges. The record 3.17 million membership base in Q1 2026, generated entirely without Cigna, proves the company can thrive as a pure-play individual insurer.
Judgment:Positive — Shedding the complex partnership simplified the business model, drastically reduced administrative drag, and allowed management to hyper-focus on the highly profitable, hyper-growth individual market.
Q7: Can Oscar Health Monetize Its ‘+Oscar’ Tech Platform as an Independent SaaS Revenue Stream?
Analysis: A core pillar of Oscar Health’s initial IPO thesis was that it wasn’t just a health insurer, but a pure technology company that could license its full-stack software (+Oscar / Campaign Builder) to other regional health plans for high-margin recurring revenue. To date, meaningful SaaS-style revenue has failed to materialize, and the company has quietly pulled back on aggressively marketing the platform to third parties, choosing instead to focus on its own insurance margins. While the tech stack provides a massive internal cost advantage (driving the SG&A ratio down to 15.2%), the thesis that Oscar will trade at 15x SaaS multiples based on software licensing is currently dead.
Judgment:Negative — Investors should evaluate Oscar Health purely as a highly efficient, tech-enabled managed care organization, not as a nascent healthcare SaaS vendor.
Q8: How Vulnerable is Oscar Health to the Retroactive CMS Risk Adjustment Transfer Mechanism?
Analysis: The Affordable Care Act utilizes a Risk Adjustment program that forces insurers with healthier risk pools to pay into a fund that subsidizes insurers with sicker populations. Because Oscar’s digital-first brand tends to attract younger, healthier, tech-savvy gig workers, it routinely owes massive transfer payments to legacy insurers. CFO Scott Blackley noted that risk adjustment transfers are estimated to consume 20% of premium revenue in 2026, up from 18.5% previously. While management claims to have priced this appropriately for 2026, the company remains structurally penalized for its success in attracting healthy members.
Judgment:Negative — The opaque, retroactive nature of CMS risk adjustment formulas remains the single largest uncontrollable threat to Oscar’s quarter-to-quarter earnings stability.
Q9: Does the $475 Million Revolving Credit Facility Indicate Hidden Liquidity Concerns for Oscar Health?
Analysis: In February 2026, Oscar Health secured a $475 million secured three-year revolving credit facility. In the context of a company holding over $4.8 billion in cash and short-term investments, this move is absolutely not a signal of distress. Rather, it is a highly sophisticated capital management tool. Insurance companies are required by state regulators to hold massive amounts of statutory capital in strict reserve. A revolving credit facility provides cheap, flexible liquidity for holding-company expenses and working capital without having to trap or liquidate yield-bearing investments held at the regulated subsidiary level.
Judgment:Positive — The facility optimizes the capital structure, proves that tier-one banks trust Oscar’s fundamental solvency, and completely removes the threat of dilutive equity raises for operational needs.
Q10: Is Oscar Health’s Shift to Virtual Primary Care Actually Lowering Its Long-Term Clinical Costs?
Analysis: Oscar Health offers $0 virtual primary care and aggressively routes members to high-performing, lower-cost specialists using its digital application. By vertically integrating the “digital front door,” Oscar intercepts patients before they visit wildly expensive, out-of-network emergency rooms. The data indicates this strategy is undeniably working. The combination of early intervention and strict network curation is a major driver behind the company outperforming legacy peers in cost containment, directly contributing to the historic 70.5% MLR recorded in Q1 2026.
Judgment:Positive — The proprietary tech stack is proving it is not just a flashy marketing gimmick; it is actively and systematically altering consumer behavior to drive down clinical claims costs, establishing a durable, long-term competitive advantage.